Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial is a research paper published in Cancer Cell (2024). On theSindex it has a DataRank of 1.3. It has been cited 59 times, with 48 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.614
From this paper's citation signal
Citation Network Contribution
0.655
From 27 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 48 citers.
NCI NIH HHS
Grant: R01 CA222203
NCI NIH HHS
Grant: U01 CA271407
NIH HHS
Grant: S10 OD028483
NCI NIH HHS
Grant: U01 CA268806
NCI NIH HHS
Grant: P30 CA047904
NCI NIH HHS
Grant: R01 CA257265
NCI NIH HHS
Grant: P50 CA254865
FWCI
10.51
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals